RP

Ravin Pawar

Active Director Director DIN 10748739
DIN 10748739 First appointment Aug 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2024
Shareholding value •••• Premium profile

About Ravin Pawar

Data last updated:

Ravin Pawar is a Director at Crescent R&D Private Limited (since 2024). The company operates in Pharma. Crescent R&D Private Limited reported revenue of ₹14.67 Cr (FY 2024).

DIN 10748739
Primary Designation Director
Industry Pharma
First Appointment 22 Aug 2024
Oldest Company Age 12 yrs
Largest company Crescent R&D Private Limited · ₹14.67 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Crescent R&D Private Limited U74900TN2014PTC096380
Director22 Aug 20242014₹14.67 Cr (FY 2024)Active

Board colleagues of Ravin Pawar

Directorship timeline

Open interactive timeline →
Crescent R&D Private Limited
Premium access

Shareholding and investment profile for Ravin Pawar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ravin Pawar

Ravin Pawar currently holds 1 directorship: Crescent R&D Private Limited (Director, since 22 Aug 2024, revenue ₹14.67 Cr (FY 2024)).

Ravin Pawar was first appointed on 22 Aug 2024 as Director at Crescent R&D Private Limited.

The current boards of Ravin Pawar's companies include Laith Khalid Aldoori (Crescent R&D Private Limited), Mohammed Khalid Al-Doori (Crescent R&D Private Limited), Samie Mohammed Aldoori (Crescent R&D Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available